Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT538 and Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Peritoneal Cancer
NCT05708924Phase 1Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT538 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose at 48 months. Started Apr 2023; status: terminated.
02
Drugs
FT538
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05708924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05708924.